Leading digital therapeutics companies form new alliance to support the adoption of therapeutic solutions across the healthcare ecosystem
Arlington, VA – October 24, 2017 – The Digital Therapeutics Alliance (DTA) launched today to broaden the understanding, adoption, and integration of digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.
Digital therapeutics represent a new generation of healthcare that uses innovative, clinically-validated disease management and direct treatment technologies to enhance, and in some cases replace, current medical practices and treatments.
DTA members and partners – including patients, healthcare providers, payers, academic institutions, technology organizations, and pharmaceutical manufacturers – will collaborate to:
“Digital therapeutics are re-writing our definition of medicine. It’s critical that industry, academia, government, and the medical community work together in the next phase of medical adoption,” said Eddie Martucci, CEO, Akili Interactive. “We’re excited to drive this effort alongside other leaders who share our dedication to rigorous clinical validation and organizational excellence in product development. It is truly a new class of medicine.”
“Digital therapeutics are at the forefront of a new era in healthcare. As the entire industry prepares for what’s next, we are excited to represent digital therapeutics in this rapidly evolving environment, working with regulators, patient advocacy groups, providers, payers, and manufacturers,” said Pierre Leurent, CEO, Voluntis.
DTx products receive regulatory clearance when used as a medical device, integrate into clinical practice, and tailor to patients’ clinical needs, goals, and lifestyles.
“Our Alliance is dedicated to advancing novel platforms and solutions that improve patients’ lives and add value to physicians, care teams, and the healthcare system,” explains Anand K. Iyer, Chief Strategy Officer, WellDoc. “These tools are used in daily life to improve patient and provider visibility into complex treatment processes and simplify pathways to better outcomes.”
“Digital therapeutics will significantly benefit individuals and communities by improving chronic disease care and treatment,” said David Van Sickle, CEO, Propeller Health. “DTA actively encourages and supports companies working to develop, trial, and market digital offerings with meaningful clinical benefits.”
Founding members include Akili Interactive, Propeller Health, Voluntis, and WellDoc.
“We encourage the continued growth of this industry through DTA’s work and initiatives,” said Sean Duffy, CEO, Omada Health, and DTA Strategic Advisor. “This specialized category of products emerged from the broader digital health category, and has quickly differentiated itself via companies’ clinical fidelity, evidence-based approaches, policy engagement, and commitment to outcome-focused reimbursement.”
Learn more at: www.dtxalliance.org.
About the Digital Therapeutics Alliance
The Digital Therapeutics Alliance represents the healthcare industry’s leading manufacturers of clinically validated digital therapeutic (DTx) solutions. DTA’s mission is to broaden the understanding, adoption, and integration of digital therapeutic solutions into mainstream healthcare through education, advocacy, and research. DTA members and partners – including patients, healthcare providers, payers, academic institutions, technology organizations, and pharmaceutical manufacturers – collaborate to enhance patient outcomes through assessing the value and impact of DTx solutions in clinical practice, constructing industry and regulatory frameworks, and encouraging data-driven integration and utilization of DTx solutions across the healthcare industry.
Digital therapeutics are clinically-validated solutions that may be used as standalone interventions or in association with other treatments to engage patients and improve the overall quality, cohesion, outcomes, and value of healthcare delivery. DTx products demonstrate safety and efficacy in randomized clinical trials, receive regulatory clearance when used as a medical device, integrate into clinical practice, and tailor to patients’ clinical needs, goals, and lifestyles. These solutions consist of patient-facing treatments, clinical assessment and outcomes tracking tools, clinician monitoring dashboards, and HIPAA-compliant data storage.
For more information visit: www.dtxalliance.org
Digital Therapeutic Alliance member company leaders Pierre Leurent, CEO, Voluntis, Anand Iyer, Chief Strategy Officer, WellDoc, and Vincent Hennemand, VP of Strategy, Corporate & BD, Akili Interactive, will present at the Frontiers Health Summit on November 17 in Berlin, Germany.
Session — Software as a drug: the dawn of Digital Therapies [Keynote and Panel]
Date — Friday, November 17, 2017 2:15pm – 3:15pm
Description — More than 150 companies are already working on digital therapeutics, and an increasing number of these are starting to show significant clinical evidence. In addition, several pharma companies have started investing in digital therapeutics companies, and are partnering to distribute digital therapeutics through their sales channels. This is a strong indication that digital therapeutics will be the “3rd wave of medicine”. Our panel will discuss the resulting industry transformation, the opportunities for healthcare providers and the pharma industry, and what efforts are underway to define new protocols of care and measures of clinical effectiveness.
For more information about the conference, visit www.frontiershealth.co.
The Digital Therapeutics Alliance is proud to participate in the Digital Therapeutics and Digital Medicine Summit to be held in San Jose, CA on Feb 27-28, 2018.
With healthcare becoming more expensive and smart devices more prevalent, digital medicine and digital therapeutics are seeking to improve patients’ lives through validated digital approaches. At this crucial point of rapid adoption, the Digital Therapeutics and Digital Medicine Summit will provide the first industry-dedicated forum to advance this new generation of healthcare.
The Digital Therapeutics and Digital Medicine Summit will serve digital therapeutic & digital medicine companies, pharma and investors who are developing digital solutions for patients in need. Specifically designed for those looking to drive forward this new treatment paradigm, the summit will address the leading scientific, tech and commercial challenges in this rapidly emerging field.
An exec-level gathering for the pioneers and future players in the industry, the Digital Therapeutics and Digital Medicine Summit will aid in defining the foundations of the field, as well as its future direction. Promoting openness and collaboration, the summit will yield genuine insights, idea sharing and investment conversations to capitalize on the potential of this digital revolution.
The Digital Therapeutics and Digital Medicine Summit will bring together the key stakeholders in the industry to connect, share knowledge and define the future of the field.
To learn more, visit: https://digitaltxsummit.com/